245 related articles for article (PubMed ID: 18084764)
1. Pharmacokinetics of heated intraperitoneal oxaliplatin.
Ferron G; Dattez S; Gladieff L; Delord JP; Pierre S; Lafont T; Lochon I; Chatelut E
Cancer Chemother Pharmacol; 2008 Sep; 62(4):679-83. PubMed ID: 18084764
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study.
Gesson-Paute A; Ferron G; Thomas F; de Lara EC; Chatelut E; Querleu D
Ann Surg Oncol; 2008 Jan; 15(1):339-44. PubMed ID: 17943387
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia.
Chalret du Rieu Q; White-Koning M; Picaud L; Lochon I; Marsili S; Gladieff L; Chatelut E; Ferron G
Cancer Chemother Pharmacol; 2014 Sep; 74(3):571-82. PubMed ID: 25053386
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of hyperthermic intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis after cytoreductive surgery.
Pérez-Ruixo C; Valenzuela B; Peris JE; Bretcha-Boix P; Escudero-Ortiz V; Farré-Alegre J; Pérez-Ruixo JJ
Cancer Chemother Pharmacol; 2013 Mar; 71(3):693-704. PubMed ID: 23274396
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.
Panteix G; Beaujard A; Garbit F; Chaduiron-Faye C; Guillaumont M; Gilly F; Baltassat P; Bressolle F
Anticancer Res; 2002; 22(2B):1329-36. PubMed ID: 12168946
[TBL] [Abstract][Full Text] [Related]
6. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution.
Elias D; Bonnay M; Puizillou JM; Antoun S; Demirdjian S; El OA; Pignon JP; Drouard-Troalen L; Ouellet JF; Ducreux M
Ann Oncol; 2002 Feb; 13(2):267-72. PubMed ID: 11886004
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis.
Ceelen WP; Peeters M; Houtmeyers P; Breusegem C; De Somer F; Pattyn P
Ann Surg Oncol; 2008 Feb; 15(2):535-41. PubMed ID: 17960463
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C.
Sugarbaker PH; Stuart OA; Carmignani CP
Cancer Chemother Pharmacol; 2006 May; 57(5):703-8. PubMed ID: 16096789
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction.
Baur M; Drescher A; Gneist M; Dittrich C; Jaehde U
Cancer Chemother Pharmacol; 2008 Jan; 61(1):97-104. PubMed ID: 17396265
[TBL] [Abstract][Full Text] [Related]
10. Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study.
Pomel C; Ferron G; Lorimier G; Rey A; Lhomme C; Classe JM; Bereder JM; Quenet F; Meeus P; Marchal F; Morice P; Elias D
Eur J Surg Oncol; 2010 Jun; 36(6):589-93. PubMed ID: 20466507
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and phase II study of heated intraoperative intraperitoneal melphalan.
Sugarbaker PH; Stuart OA
Cancer Chemother Pharmacol; 2007 Feb; 59(2):151-5. PubMed ID: 17091250
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of oxaliplatin after intraperitoneal administration with hyperthermia in Wistar rats.
Mas-Fuster MI; Ramon-Lopez A; Lacueva FJ; Arroyo A; Más-Serrano P; Nalda-Molina R
Eur J Pharm Sci; 2018 Jul; 119():22-30. PubMed ID: 29626594
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic analysis of hyperthermic intraperitoneal oxaliplatin-induced neutropenia in subjects with peritoneal carcinomatosis.
Valenzuela B; Nalda-Molina R; Bretcha-Boix P; Escudero-Ortíz V; Duart MJ; Carbonell V; Sureda M; Rebollo JP; Farré J; Brugarolas A; Pérez-Ruixo JJ
AAPS J; 2011 Mar; 13(1):72-82. PubMed ID: 21210260
[TBL] [Abstract][Full Text] [Related]
14. Hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal carcinomatosis arising from appendix: preliminary results of a survival analysis.
Marcotte E; Sideris L; Drolet P; Mitchell A; Frenette S; Leblanc G; Leclerc YE; Dubé P
Ann Surg Oncol; 2008 Oct; 15(10):2701-8. PubMed ID: 18654822
[TBL] [Abstract][Full Text] [Related]
15. Hyperthermic intraperitoneal perfusion chemotherapy--views on the observed variability in oxaliplatin pharmacokinetics.
Srinivas NR
Eur J Clin Pharmacol; 2009 Mar; 65(3):321-2. PubMed ID: 19011850
[No Abstract] [Full Text] [Related]
16. Heated intra-operative intraperitoneal oxaliplatin alone and in combination with intraperitoneal irinotecan: Pharmacologic studies.
Elias D; Raynard B; Bonnay M; Pocard M
Eur J Surg Oncol; 2006 Aug; 32(6):607-13. PubMed ID: 16621432
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the risk of contamination of surgical personnel by vaporization of oxaliplatin during the intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC).
Guerbet M; Goullé JP; Lubrano J
Eur J Surg Oncol; 2007 Jun; 33(5):623-6. PubMed ID: 17408909
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure.
Cotte E; Colomban O; Guitton J; Tranchand B; Bakrin N; Gilly FN; Glehen O; Tod M
J Clin Pharmacol; 2011 Jan; 51(1):9-18. PubMed ID: 20173087
[TBL] [Abstract][Full Text] [Related]
19. Which method to deliver hyperthermic intraperitoneal chemotherapy with oxaliplatin? An experimental comparison of open and closed techniques.
Ortega-Deballon P; Facy O; Jambet S; Magnin G; Cotte E; Beltramo JL; Chauffert B; Rat P
Ann Surg Oncol; 2010 Jul; 17(7):1957-63. PubMed ID: 20143265
[TBL] [Abstract][Full Text] [Related]
20. Rate and extent of oxaliplatin absorption after hyperthermic intraperitoneal administration in peritoneal carcinomatosis patients.
Pérez-Ruixo C; Peris JE; Escudero-Ortiz V; Bretcha-Boix P; Farré-Alegre J; Pérez-Ruixo JJ; Valenzuela B
Cancer Chemother Pharmacol; 2014 May; 73(5):1009-20. PubMed ID: 24663502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
